[go: up one dir, main page]

MX2015000442A - Composiciones vacuna. - Google Patents

Composiciones vacuna.

Info

Publication number
MX2015000442A
MX2015000442A MX2015000442A MX2015000442A MX2015000442A MX 2015000442 A MX2015000442 A MX 2015000442A MX 2015000442 A MX2015000442 A MX 2015000442A MX 2015000442 A MX2015000442 A MX 2015000442A MX 2015000442 A MX2015000442 A MX 2015000442A
Authority
MX
Mexico
Prior art keywords
vaccine compositions
protecting
useful
relates
human subject
Prior art date
Application number
MX2015000442A
Other languages
English (en)
Other versions
MX381497B (es
Inventor
Alain Bouckenooghe
Remi Forrat
Jean Lang
Mélanie Saville
Nadia Tornieporth
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of MX2015000442A publication Critical patent/MX2015000442A/es
Publication of MX381497B publication Critical patent/MX381497B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a composiciones vacuna que son útiles en un método de protección de un sujeto humano contra la enfermedad del dengue.
MX2015000442A 2012-07-24 2013-07-24 Composiciones vacuna. MX381497B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305907 2012-07-24
EP12305912 2012-07-25
PCT/EP2013/065667 WO2014016360A1 (en) 2012-07-24 2013-07-24 Vaccine compositions

Publications (2)

Publication Number Publication Date
MX2015000442A true MX2015000442A (es) 2015-03-12
MX381497B MX381497B (es) 2025-03-12

Family

ID=48875047

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015000442A MX381497B (es) 2012-07-24 2013-07-24 Composiciones vacuna.
MX2021004211A MX2021004211A (es) 2012-07-24 2015-01-09 Composiciones vacuna.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021004211A MX2021004211A (es) 2012-07-24 2015-01-09 Composiciones vacuna.

Country Status (11)

Country Link
US (2) US20150196631A1 (es)
EP (2) EP2877208B1 (es)
JP (2) JP2015524421A (es)
KR (2) KR20200067938A (es)
CN (1) CN104812407B (es)
AU (1) AU2013295014B2 (es)
MX (2) MX381497B (es)
MY (2) MY197723A (es)
PH (1) PH12014502840B1 (es)
SG (2) SG10201912291YA (es)
WO (1) WO2014016360A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150036593A (ko) * 2012-07-24 2015-04-07 사노피 파스퇴르 뎅기열 바이러스 감염 예방용 백신 조성물
MX374519B (es) 2013-03-15 2025-03-06 Us Gov Health & Human Services Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
TWI852899B (zh) * 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
WO2016130321A1 (en) * 2015-02-09 2016-08-18 Academia Sinica An epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
WO2017005652A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
EP3147294B1 (en) * 2015-09-24 2020-04-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing dengue virus infections from other flaviviral infections using a recombinant mutant envelope protein
BR112018010690A8 (pt) * 2015-11-27 2019-02-26 The Chemo Sero Therapeutic Res Institute vírus vivo tendo um banco de cepas atenuadas do vírus da dengue, e uma vacina da dengue contendo as mesmas como antígenos
WO2017179017A1 (en) 2016-04-13 2017-10-19 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
WO2018208741A1 (en) 2017-05-08 2018-11-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and compositions for the detection of flavivirus infections
EP3691681A1 (en) * 2017-10-05 2020-08-12 Sanofi Pasteur Compositions for booster vaccination against dengu
US11491217B2 (en) 2017-12-06 2022-11-08 Emory University Chimeric viruses encoding mutant zika virus envelope glycoproteins
EP3549603A1 (en) 2018-04-06 2019-10-09 Sanofi Pasteur Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
AU2019335006B2 (en) 2018-09-05 2024-07-04 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
CN112079934B (zh) * 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US109A (en) 1836-12-15 Erawijtg
US5422A (en) 1848-02-01 Spark-arrester
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
CZ300172B6 (cs) 1997-02-28 2009-03-04 Acambis Inc. Chimerický živý, infekcní, oslabený virus, lécivopro prevenci nebo lécbu flavivirových infekcí s jeho obsahem a molekula nukleové kyseliny jej kódující
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6511667B1 (en) 1999-03-26 2003-01-28 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-2 virus vaccine
JP2002540166A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱３型ウイルスワクチン
CA2368673A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
CA2365728A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-1 virus vaccine
PT2278012E (pt) 2000-02-16 2015-11-30 Univ Mahidol Quimeras imunogénicas do vírus do dengue 2
DK1159968T3 (da) 2000-05-30 2009-02-23 Univ Mahidol Attenuerede stammer af Dengue-virus og deres anvendelse i en vaccinesammensætning
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
DK1402075T3 (da) 2001-05-22 2013-02-11 Us Gov Nat Inst Health Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira
JP2005518332A (ja) 2001-05-23 2005-06-23 デンドレオン コーポレイション 細胞表面のプロテアーゼにより活性化される結合体およびその治療的使用
EP1401859B1 (en) 2001-06-01 2013-08-07 Sanofi Pasteur Biologics Co. Chimeric flavivirus vectors
KR101074175B1 (ko) * 2002-01-15 2011-10-14 사노피 파스테르 바이오로직스 씨오 플라비바이러스 백신
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
ATE475706T1 (de) 2005-06-17 2010-08-15 Sanofi Pasteur Abgeschwächter dengue-serotyp-2-stamm
WO2006134433A1 (en) 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 1 attenuated strain
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
BRPI0614265A2 (pt) 2005-08-10 2011-03-22 Acambis Inc uso de uma vacina do vìrus da febre amarela e de uma vacina de flavivìrus quimérico e kit contendo referidas vacinas
CN104984352A (zh) * 2005-11-21 2015-10-21 圣诺菲·帕斯图尔有限公司 重组病毒的稳定制剂
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition

Also Published As

Publication number Publication date
CN104812407B (zh) 2022-11-22
SG10201912291YA (en) 2020-02-27
KR20150036592A (ko) 2015-04-07
MY168959A (en) 2019-01-28
EP2877208B1 (en) 2021-05-12
JP6830118B2 (ja) 2021-02-17
CA2878682A1 (en) 2014-01-30
EP2877208A1 (en) 2015-06-03
AU2013295014A1 (en) 2015-01-29
HK1212906A1 (zh) 2016-06-24
MX2021004211A (es) 2021-05-27
PH12014502840A1 (en) 2015-02-23
US20190201517A1 (en) 2019-07-04
MY197723A (en) 2023-07-10
KR20200067938A (ko) 2020-06-12
JP2015524421A (ja) 2015-08-24
EP3932422A1 (en) 2022-01-05
SG11201500412TA (en) 2015-02-27
AU2013295014B2 (en) 2018-01-18
CN104812407A (zh) 2015-07-29
JP2019151636A (ja) 2019-09-12
US20150196631A1 (en) 2015-07-16
WO2014016360A1 (en) 2014-01-30
PH12014502840B1 (en) 2015-02-23
MX381497B (es) 2025-03-12

Similar Documents

Publication Publication Date Title
MX2015000442A (es) Composiciones vacuna.
GT201500005A (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
MX2017001279A (es) Usos y composiciones de la flagelina.
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
CO7151535A2 (es) Evento de maiz mon 87411
MX2016001236A (es) Anticuerpos anti-fgfr2iiib afucosilados.
MX367521B (es) Composiciones de insulina de rápida acción.
DK2912074T3 (da) Dermal injicerbar steril sammensætning
PT2852389T (pt) Composições que compreendem benzodiazepinas de ação rápida
EP2895139A4 (en) COMPOSITIONS AND METHODS FOR DENTAL TREATMENT
BR112015012907A2 (pt) composição de cuidado pessoal
CR20140594A (es) Composiciones farmacéuticas y tratamiento de mastitis
EP2906178A4 (en) REMINERALIZATION AND DEENSITIZATION COMPOSITIONS, TREATMENTS AND METHODS OF MANUFACTURE
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
MX357656B (es) Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
EP2957276A4 (en) TOOTH WHITENING COMPOSITION
EP2883433A4 (en) Tiller tine
MX2015005846A (es) Copolimeros de bloque para proteccion del esmalte dental.
NZ709664A (en) Use of fenugreek extract to enhance female libido
MX2015006999A (es) Usos de extracto de bacopa monnieri.
IN2014MN02422A (es)
CR20120166A (es) Composiciones y productos antimicrobianos
EP2914233A4 (en) DENTAL COMPOSITIONS
IN2014KN01772A (es)